Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Jennifer Riley as chief strategy officer (CSO), a newly created role effective January 1, 2025.
Ms. Riley will oversee corporate strategy, as well as commercial and product pipeline planning, with a focus on driving growth and innovation across the organization.
In a statement, Dr. Garry Neil, CEO and chairman of the board, said, “We are thrilled to welcome Jennifer to Avalo in the newly established role of CSO.”
“Jennifer brings extensive leadership experience, strategic acumen, and deep expertise in immunology, which will be invaluable as we advance our lead asset, AVTX-009, an anti-IL-1β monoclonal antibody currently in the LOTUS Phase 2 trial for hidradenitis suppurativa. This role is pivotal for Avalo as we refine our commercialization strategies and explore indication expansion,” Dr. Neil added.
Ms. Riley stated, “I am honored to join Avalo Therapeutics at such an exciting and transformative time for the company.”
“This is a compelling role given the significant opportunity for AVTX-009 as a potential best in disease treatment for HS, a condition with high unmet need and a rapidly growing therapeutics market that is forecast to exceed $10 billion in the coming years. Furthermore, there is strong clinical rationale for the role of IL-1β in additional indications and I am excited about the possible expansion of the program into other large inflammatory market opportunities. I look forward to collaborating with the talented team at Avalo to advance the company’s mission of delivering impactful therapies that address immune dysregulation and improve the lives of patients in need,” she added.
